Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoPE Pilot: IV Psilocybin in Sleeping Participants
NCT05592379Phase 1Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2023
- Primary completion
- Feb 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1 trial of psilocybin (7 arms), sponsored by University of Wisconsin–Madison. Primary endpoint: Number and nature of adverse events up to 9 days. Started Nov 2023; status: completed.
02
Drugs
psilocybin
Beyond the preview
Go deeper on NCT05592379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05592379.